NDAOPHTHALMICOINTMENT
Approved
May 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
LUMI-SPORYN (bacitracin zinc; neomycin sulfate; polymyxin b sulfate) by R-Pharm US. Approved for infection in minor:. First approved in 1971.
Drug data last refreshed 7h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LUMI-SPORYN is a fixed-dose triple antibiotic combination (bacitracin zinc, neomycin sulfate, polymyxin B sulfate) administered as an ophthalmic ointment. It treats minor eye infections by providing broad-spectrum bactericidal coverage against common ocular pathogens. The three antibiotics work synergistically to inhibit bacterial cell wall and protein synthesis.
LOE Approaching
As a 50+ year-old generic-adjacent product approaching loss of exclusivity, LUMI-SPORYN likely operates with a small, maintenance-focused commercial team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
Working on LUMI-SPORYN offers exposure to lifecycle management of legacy products, supply chain optimization, and regulatory compliance in a stable, low-growth environment. This role is suited for professionals seeking predictable operations work rather than high-intensity commercial expansion or clinical innovation.
Supply Chain Manager
Worked on LUMI-SPORYN at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.